Cambridge Innovation Capital (CIC), a leading investor in life sciences and deep tech companies, today announced its role as a co-lead investor in TRIMTECH Therapeutics’ $31 million (£25 million) seed funding round. The financing round, which was oversubscribed, was also co-led by SV Health Investors’ Dementia Discovery Fund (DDF), with M Ventures and Pfizer Ventures joining. Additional investors include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon.

TRIMTECH Therapeutics, a biotech company pioneering targeted protein degradation (TPD) for neurodegenerative disease treatment, is developing a pipeline of potent, CNS-penetrant therapeutics based on its proprietary TRIMTAC™ aggregate-selective degrader molecules. The company’s platform leverages the innate properties of the E3 ubiquitin ligase TRIM21 to selectively and potently degrade protein aggregates associated with severe neurological and inflammatory conditions such as Alzheimer’s and Huntington’s disease.

Michael Anstey, Partner at Cambridge Innovation Capital “CIC is proud to have played a key role in the formation and funding of TRIMTECH Therapeutics. With over 55 million people worldwide affected by Alzheimer’s and millions more suffering from other neurodegenerative disorders, TRIMTECH’s groundbreaking approach has the potential to transform treatment options and improve patient outcomes. This investment underscores our commitment to backing world-class science with the potential to address major unmet medical needs.”

TRIMTECH was founded by CIC and DDF in collaboration with their entrepreneur-in-residence, Damian Crowther, along with academic co-founders Leo James (MRC Laboratory of Molecular Biology) and Will McEwan (UK DRI at the University of Cambridge). The financing will enable TRIMTECH to further develop its innovative therapeutic pipeline and accelerate progress toward clinical applications.

Nicola Thompson, CEO, TRIMTECH, said: “This oversubscribed financing round and the outstanding quality of our investor syndicate is a great endorsement of TRIMTECH’s unique approach to targeting the selective removal of aggregated proteins that underpin so many CNS diseases, and recognises our impressive scientific foundations and world-class team. We extend our thanks to all of our supporters and look forward to working with the new Board members, as we now push forward with progressing the pipeline.”